PeptidePedia The community reference

Weight regain after discontinuation (revision 1)

Old revision·09:10, 5 Sep 2024·StopperingSteff

This is an old revision of this page, as it stood at 09:10, 5 Sep 2024, saved by StopperingSteff with the summary new article: adverse effects, expansion welcome. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Weight regain after discontinuation
Evidence designRandomised withdrawal after a lead-in
Principal trialsSTEP 4, SURMOUNT-4
Observed patternSteady regain towards baseline
Topic infobox · conventions

Weight regain after discontinuation is the return of body weight towards its pre-treatment value when incretin therapy stops. It has been documented in randomised withdrawal trials, which are the design capable of distinguishing it from the natural course of weight in a treated population.[1]

In STEP 4, participants who had reached the maintenance dose during a 20-week run-in were randomised to continue or to switch to placebo. Those continuing lost further weight; those switched regained steadily over the following 48 weeks.[1]

References

  1. ^ a b Rubino D, Abrahamsson N, Davies M, et al. "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4)." JAMA 325(14):1414–1425 (2021). PMID 33755728.